Biblio
Export 2680 results:
[ Author
Filters: First Letter Of Keyword is A [Clear All Filters]
“Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
, “Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.”, J Alzheimers Dis, vol. 51, no. 1, pp. 277-91, 2016.
, “Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.”, J Alzheimers Dis, vol. 51, no. 1, pp. 277-91, 2016.
, “Diagnostic Assessment and Management of Dysphagia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 947-55, 2016.
, “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
, “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
,